Eli Lilly and Company (NYSE:LLY):
JardianceÂ® (empagliflozin) tablets to be studied in chronic kidney disease.
The company is so far trading up by 1.17% since yesterday’s close of $80.1.
Additionally the company declared a dividend paid on Friday the 9th of June 2017. The dividend payment was $0.520 per share for the quarter which is $2.08 annualized. This dividend amount was represent a yeild of $2.57. The ex-dividend date was set for Thursday the 11th of May 2017.
Eli Lilly and Company, launched on January 17, 1901, is involved in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Business’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Business’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries..
Shares are trading at $81.04 a tad above $80.11, the stock’s 50 day moving average and a bit higher than the 200 day moving average of $78.56. The 50 day moving average went up $0.93 or +1.16% and the 200 day average moved up $2.48.
The company currently has a P/E ratio of 39.19 and the market value is 85.60B. In the last earnings report the EPS was $2.07 and is projected to be $4.12 for the current year with 1,056,300,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $1.05 and the next full year EPS is anticipated to be $4.37.
Several analysts have provided guidance on Eli Lilly and Company. On November 25 the company was downgraded to “Market Perform” from “Outperform” with a current price target of $64.00 in a report issued by BMO Capital. BMO Capital downgraded the stock and lowered the price target on November 25 changing the price objective from $100.00 to $64.00 and altering the rating from “Outperform” to “Market Perform”.
On November 25, 2016 the stock rating was rated “Neutral” by Atlantic Equities down from the previous “Overweight” rating. On September 8 the stock rating was upgraded from “Neutral” to “Overweight” in an announcement from JP Morgan.
May 2 investment analysts at Leerink Swann held the stock rating at “Outperform” but moved up the price target to $91.00 from $90.00. On May 1 Credit Suisse made no change to the stock rating of “Outperform” and lowered the price expectation from $105.00 to $91.00.